DataMeds AI files draft information statement
MEDS•DataMeds AI filed a draft information statement after shareholders authorized 1 million shares of blank-check preferred stock, including 25,000 shares designated as Series A Convertible Preferred Stock tied to conversion of $21,132,812.50 in May 2026 Notes.
1. Preferred stock authorization
Shareholders authorized an amendment adding 1 million shares of blank-check preferred stock, giving the board flexibility to set terms for new series, including voting, dividend, liquidation and conversion rights. The plan includes designating 25,000 shares as Series A Convertible Preferred Stock tied to conversion of the May 2026 Notes, which total $21,132,812.50 in principal; PIPE Warrants cover up to 8,298,225 common shares at $7.50.
2. Other shareholder votes
Shareholders also authorized five directors and ratified Suri & Co. as auditor for fiscal 2026.
